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INTRODUCTION 
 
 
 ABBREVATIONS 
AP-1-Activator Protein -1 
DNA-Deoxyribonucleic Acid 
EGF-Epidermal Growth Factor 
ERE-Estrogen Response Element 
ER-Estrogen Receptor 
ER-α/ESR1-Estrogen Receptor Alpha 
ER-β/ESR2-Estrogen Receptor Beta 
GnRH-Gonadotrophin Releasing hormone 
Her2/neu-Human Epidermal Growth Factor Receptor 2  
hsp-Heat Shock protein  
mTOR-Mammalian Target Of  Rapamycin  
NST-NoSpecial Type 
PCR-Polymerase Chain Reaction  
PR-Progestrone Receptor 
RLN-Regional Lymphnode  
RNA-Ribonucleic Acid 
SHBG-Sex Hormone Binding Globulin  
SNP-Single Nucleotide Polymorphism 
WHO-World Health Organisation 
 INTRODUCTION  
Seldom has a disease evoked more interest and dreadful fear in  the common 
man like it has for cancer. Breast cancer, amongst all cancers,continue to evoke 
such responses and even more research, especially since the treatment involves 
surgery which leaves physical and emotional scars in its victims. 
Breast carcinoma is the commonest cancer in women. It is the  leading cause 
of death in women, with more than one million cases occuring worldwide 
annually .Breast cancer represent an important public health issue, having a high 
occurence worldwide, with an obvious increasing tendency.(2). 
In high income countries breast cancer is the predominant cause for 
mortality in females aged 20-59years. 
The Edwin Smith Surgical Papyrus is having the first reference to breast 
cancer.This surgical text,described in hieractic script, is the incomplete copy of an 
original record  that  dates back to the pyramid age of Egypt(3000-2500BC).(3). 
The incidence of  cancer has been on rise worldwide .Breast cancer 
incidence accounts for 16% of all breast cancers,as per the WHO cancer control 
and prevention programme.It is calculated that 51,9000 women died owing to 
breast malignancy in 2004.Inspite of the fact, breast cancer is thought to be a 
disease of the developed world,  majority of   breast cancer mortality(69%) ,  is  in  
developing countries (4). Hence .breast cancer has emerged to be one of the 
leading  cancer killer amongst women worldwide. 
Over the last few decades there have been better advances in breast cancer. 
Earliest detection  and skillfull  treatment has leading to significant decline  in 
breast cancer deaths.  It has  also made improved outcome for women living with 
disease. Breast cancer is no longer seen as single disease but rather a multifaceted 
disease consisting of diverse biological subtypes with distinct  natural history. 
Breast cancer presents as a varied spectrum of clinial ,pathological and molecular 
features with diverse  prognostic and therapeutic implications. 
Estrogen is the steroid hormone, responsible for development and 
maturation of primary and  secondary sexual characteristics in 
females.(5).Estrogen has  an important role   in pathogenesis and development  of 
breast cancer(6). 
Estrogen receptor is an intracellular protein molecule.  They are targets for 
estrogen action. Estrogen receptor normally resides in cells nucleus ,along with 
DNA molecules. Estrogen receptor alpha gene polymorphism leads to alteration in 
estrogen  receptor  function  in breast cancer(7). This study is aimed to ascertain  
whether Pvull polymorphism in ER alpha gene  has  a role in the causation of 
breast cancer. 
 
  
 
 
 
 
 
   
 
 
 
 
 
 
  
 
 
 
 
 
AIMS AND OBJECTIVES 
 AIMS AND OBJECTIVES 
PRIMARY AIMS AND OBJECTIVES: 
1. To assess  ER-α gene polymorphism is the cause of difference in breast 
cancer susceptibility among any population 
2. To correlate  ER-α genotype expression with estrogen receptor expression  
in cancer cells 
3. Whether there is any association between the  stage of tumour and specific  
ER-α genotype 
SECODARY AIMS AND OBJECTIVES 
1. To  correlate the ER-α geneotype frequency and Body mass index among 
breast cancer patients 
2. To analyse  ER-α genotype frequency distribution of Pvull polymorphism 
between pre and postmenopausal women with breast cancer 
 
 
 
  
 
 
 
 
 
 
 REVIEW OF LITERATURE 
 REVIEW OF LITERATURE 
Breast anatomy and development provide a foundation for understanding the 
types of breast cancer that occur and the hormonal factors that influence breast 
cancer cell growth. 
Normal breast tissue: 
Human breasts are composed of parenchymal tissues consisting of a 
branching ductal system radiating from the nipple. The breast parenchyma consists 
of 15-20 mammary lobes,.Each lobule drains to nipple  by lactiferous duct. They 
are seperated from one another by interlobar connective tissue.Just before entering 
the nipple,each of the 15-20 main ducts expands into a dilated segment called the 
lactiferous sinus.Each lobe consists of 30-80 lobules,which contain the milk-
producing elements of the breast.The lobules in turn are composed of 20-40 
terminal units or acini, which are surrounded by hormonally responsive intralobar 
connective tissue.(8).The proportion of fat,fibrous and parenchymal tissue vary 
greatly between individuals and with menopausal status ,weight,number of live 
births and genetic factors.(9 ). 
 
Rudimentary breast development begins in utero and then the anatomy 
undergoes distinct changes at the puberty,during menstruation,with pregnancy and 
lactation and finally at menopause. At birth ,a female infant has nipples and 
rudimentary ductal system .At puberty,under the influence of  GnRH, anterior  
pituitary secretes Follicle stimulating hormone(FSH) and Lutenizing hormone 
(LH) .FSH and LH inturn stimulates ovaries to produce  estradiol . 
The Estrogens ,primarily 17-estradiol,stimulate the growth and development 
of breasts. It takes one to two years after menarche before the ovarian follicles are 
fully mature and begin to ovulate and produce progestrone. Estrogen and 
progesterone together contribute to the full development of ducts,lobules and 
alveoli. Fluctuations in estrogen and progesterone levels during a normal menstrual 
cycle influences breast morphology. During the first half of the menstrual cycle 
(follicular phase) ,under the influence of FSH and LH,estrogen levels increase and 
peak halfway through the cycle.Ovulation occurs and then a second peak of 
estrogen occurs in the second half of the cycle(luteal phase) when the progesterone 
levels peak. Estrogen and progesterone promote the development of ducts and 
alveoli respectively in the mammary glands(11). 
CARCINOMA OF THE BREAST 
Breast cancer develops due to  uncontrolled growth of the epithelial cells at the 
junction of the terminal duct-lobular unit. It has been calculated  that most breast 
cancers need about 5-10 years to develop from a single malignant cell to a tumour 
of 5-10mm diameter(12). 
EPIDEMIOLOGY 
Globally,Breast cancer is the most common neoplasm   affecting females. It  
comprises about  25% of all new cases of cancer (13).Breast cancer incidence are 
low in less developed countries and in Japan than in industralised countries.In 
2000,global incidence of breast cancer is over 10 million in which 5.5 million 
cases are seen in developing countries.(14). 
Cervical cancer incidence are higher in developing countries than breast 
cancer,the reverse holds true in developed countries.. 
 In India ,breast cancer is the second most common cancer in women after 
cervical cancer. However in Indian metropolitan areas, breast cancer became most 
common cancer than  cervical cancer  (15) 
Breast cancer incidence rate shows geographical variation  largely because 
of  socio-economic,reproductive,hormonal,nutritional and genetic factors. Highest 
incidence rates are seen in NorthAmerica and Europe.Asia and Africa has the 
lowest incidence rates of breast cancer(16). 
After remaining constant for many years,the incidence of breast cancer 
began to increase .This is due to detection of increased number of cases by means 
of introduction of mammographic screening in early 1980’s.(17). 
The main aim of screening is the detection of small predominantly ER 
positive invasive carcinomas and insitu carcinomas .DCIS is almost exclusively 
detected by mammography ,providing an explanation for sharp increase in the 
diagnosis of DCIS since 1980. 
From 2001 to 2004 ,the incidence of Estrogen receptor  positive invasive 
breast cancer  has  raised. The reason for this trend is multifactorial.  This may be  
attributed that ,in 2002 many women stopped using hormone replacement therapy . 
During the 1980’s the number of women dying of breast cancer remained  
constant ,while the incidence of breast cancer was increasing. Since 1994,the 
breast cancer mortality rate for all women has slowly declined from 30% to 
20%.The  decrease is attributed to the detection of clinically significant cancers at 
a curable stage due to screening,as well as better and effective treatement 
modalities(18) 
ETIOLOGY AND RISK FACTORS 
Breast cancer is a multifactorial disease ,meaning a variety of factors 
contribute to the biologic processes involved in carcinogenesis. Some of these 
factors are genetic changes in oncogenesis and in tumour suppressor genes, growth 
factor imbalances,enzyme production and telomerase activity. These genetic 
changes interact with non genetic factors such as environment, nutrition and other 
lifestyle risk factors leading to cancer. By  identification of modifiable risk factors 
and controlling them, the risk  of breast cancer has been lowered. 
Any factor, such as ovarian hormones and growth factors, that increases 
cellular proliferation   in breast epithelium raises the risk .  Increased cell 
proliferation  increases the opportunities for spontaneous genetic damage leading 
to breast cancer risk.(19). 
Reproductive Risk Factors: 
Early  Menarche and late Menopause: 
Early age at menarche increases risk of breast cancer .In general for every 
one year delay breast cancer frequency decreases  by 10-20%.  
Both  age of onset of menarche and regular cycles influence the risk of 
breast cancer. Breast cancer risk may be explained by  effect of early  menarche on 
estrogen level.(20) 
Women with surgically induced menopause have been shown to have 
reduced risks of breast cancers compared to women whose menopause occurred 
naturally.In comparison with  women whose menopause occurs between the ages 
of 45 and 54(relative risk 1),women with late menopause at age more than 55 years 
have a relative risk of 1.48.Increased risk of breast cancer in late menopause is due 
to long menstrual history and ovarian function (21).   
Parity  
Early age at first pregnancy  decreases risk of breast cancer.17-41% 
reduction in breast cancer risk  is seen in parous women when compared to 
nullipara(22).These  reduction   is not immediately found in parous women. 
Actually the  risk is increased in the first  ten or more years following pregnancy.It 
may be explained by  proliferatve changes in pregnancy.Breast cancer risk is 
decreased by 7% for every childbirth thereafter. This reduction is attributed to 
maximum differentiation in breast parenchyma   in which further DNA damage 
does not takes place. 
Age at First Live Birth 
 Early  first pregnancy leads to maturation of terminal ductal lobular unit of 
breast thereby reducing risk of breast cancer. Hence.women who are more than 35 
years of age had 60% increase in breast cacer than those are less than 18years of 
age at first pregnancy (23).  
 Breast feeding 
 Breast feeding further reduces risk of breast cancer in parous women. There 
is about 12% decrease in  relative risk of breat cancer development for women who 
breast feed for one year. (24).This reduction percentage is increased upto 50% in 
high parity females. 
Breastfeeding is thought to decrease   breast cancer risk by lessening  the 
total number of  menstrual cycles and consequently cumulative ovarian hormone 
exposure . 
Hormones  
Reproductive risk factors are well known to influence breast cancer risk by 
modulating endogenous hormone levels.  In the following sections, the relation 
between serum hormonal  levels and breast cancer risk will be discussed. 
Estrogens and Androgens 
Estrogen increases cell proliferation in the breast.  In premenopausal 
women, nearly all estrogen is of ovarian origin.  After menopause, direct   ovarian 
production stops and most estrogen is derived from the aromatization of adrenal 
androgens .  
Estradiol and estrone sulfate are the types of estrogen implicated in breast 
cancer development.The 17β estradiol is the most functionally active form of 
estrogen from puberty till menopause. Estradiol  circulates in the blood either as 
free hormone or  bound to sex hormone –binding globulin(SHBG)  and albumin. 
Free estradiol or estrogen which binds to albumin are functionally more active 
forms.Major circulating estrogen  is estrone sulfate. They are the majour resource 
of estrogen from adipose tissue  in postmenopausal females. 
Androgens such as testosterone and androstenedione can be aromatized into 
estrogens, either in the ovaries or in adipose tissues.Estrogen  is  derived directly 
from ovarian and adrenal synthesis as well as from the peripheral conversion of 
androstenedione.  
Breast cancer risk  is directly proportional to the levels of  serum 
concentrations of sex hormones including total and free estradiol, androstenedione, 
and testosterone (25). 
Serum estradiol levels have been shown to be be less in Asian women 
regardless of menopausal status. These differences seen in low risk population may 
be due to reduced number of ovulatory cycles as a result of late age at menarche, 
higher parity,frequent  breastfeeding ,breast feeding for  longer durations, and early 
age at menopause. 
In postmenopausal women , weight is directly propotional to plasma levels 
of estrone and estradiol,as well as unbound estradiol to SHBG. Hence 
postmenopausal obese women have greater risk of breast cancer development than 
in nonobese women. 
Hormone Replacement Therapy 
 Invasive  breast cancers occur more among the current users of hormone 
replacement therapy especially those who have used more than five or more years. 
However the risk of breast cancers is no higher among former users who have 
stopped taking hormones more than 5 years previously, than the risk among never 
users. Hence the major consequence  of hormone replacement therapy  is 
promotion of cancer growth rather than direct genotoxic effect. 
Breast cancer risk is increased by 2.3% for each year  among women using 
hormone replacement therapy currently ,or who have stopped within one to four 
years. The relative risk for breast cancer is 1.35  for women who had used hormone 
replacement therapy for more than 5 years.(26) 
Anthropometric Risk Factors 
The correlation  between weight and breast cancer risk differs according to 
menopausal status. Increased weight or BMI has been shown to lessen breast 
cancer development  in premenopausal but increases risk in postmenopausal  
women. 
Several hypothetized  mechanisms exist to explain the low risk of  breast 
cancer in  obese premenopausal women .  Obese premenopausal women have 
decreased progesterone levels because obesity may cause anovulation and a 
reduced  progesterone  secretion in the luteal phase . Also, leptin levels, which 
increase with increasing fat stores, inhibit ovarian estrogen production, and may 
thereby derease breast cancer development in obese premenopausal women . 
Obesity  increases breast cancer risk in postmenopausal women by 
increasing levels of endogenous estrogen (27).  The principal source of estrogen in 
postmenopausal female  is the conversion of androstenodione to estrone  in adipose 
tissue.  Also, sex-hormone-binding globulin levels fall when BMI is increased, 
thus increasing the levels of free estradiol . In addition, obesity may increase the 
concentration of several circulating cytokines, which   stimulate the activities of 
the enzymes, involved in the synthesis of estrogen . 
Family History of Breast Cancer / Genetic Factors 
Family history of breast cancer is one of the most well-established risk 
factor for  breast cancer.Some family history are important,while others are of little 
consequence.Most women who have relatives, who have  developed  breast cancer 
postmenopausally are not genetically predisposed to breast cancer and their 
increased risk is low.On the other hand, a women who has first  degree relatives 
with breast cancer have substantially increased risk of breast cancer. Risk is about 
1.5-2 times above in the woman who have  no affected first degree relative.The 
risk may be further increased to 6 if more than one, first degree relative has been  
affected. Cancers develop in these  population at an earlier age  in their  mother or 
sister. Also they have inherited DNA mutation of BRCA 1 or BRCA 2 gene, that 
increases the  risk of breast cancers.  
Lynch, distinguishes familial breast cancer from hereditary breast  cancer. Familial 
breast cancer is defined as “Family having  more than two first degree relatives 
with breast cancer in the absence of hereditary breast cancer”.Hereditary breast 
cancer is  defined as”Pattern within  a particular family   having  Mendelian 
segregation of breast cancer”. The former are probably events that may happen,by 
the laws of probability to cluster in a family,while the latter cancers are likely the 
results of inheritance of abnormal DNA.(28) 
Genetic factors  have a role in approximately 5% of all breast cancer cases,. 
But  the risk percentage  increases to  25% of cases below   30 years of age.  
Several genes are implicated in l breast cancer development.  BRCA 1   gene 
located on chromosome 17 and BRCA 2 present on chromosome 13 are associated 
with majority of inherited breast cancers. 2-5% of  breast cancers  are hereditary 
.BRCA 1 and BRCA 2 are the tumour suppressor genes with numerous important 
cell functions.It  includes  gene transcription, regulation of cell cycle check points 
and DNA repair.   
 
OTHER GENES: 
Many genes other than BRCA are involved in breast cancer risk. Women 
with  Li-Fraumeni syndrome have increased risk in development of early onset of 
many cancers including breast cancer.This syndrome is due to  mutations in p53 
tumour suppressor gene In Ataxia telengiectasia,there is 100 fold increase in breast 
cancer risk in women.It is the autosomal recessive syndrome due to DNA repair 
defect.Women with Cowden disease having mutation in the PTEN tumour 
suppressor gene develop breast cancer by 50 years of age. 
Hence,Breast cancer may also develop due to alleles with low to moderate 
penetrance.They confer lesser risk,but attributable risk is more when it is common 
in the population.Breast Cancer Association study  implies  that  larger samlple 
size is required to clarify association of polymorphism  with breast cancer .(29) 
Genetic susceptibility  due to both high and low penetrance gene mutation, 
together with interaction of environmental factor leads to increased incidence of 
breast cancer. 
Medical History 
Benign Breast Diseases 
Certain types of benign breast diseases have  increased risk of breast cancer. 
Women with benign breast disease without hyperplasia have a 1.5 fold increased 
risk of breast cancer compared to normal population.. The risk of  breast  cancer 
among women with hyperplasia varies with presence of atypia or not. 
 Atypical hyperplasia increases, 2.6 fold  risk of breast cancer as compared 
to 1.8 fold increased risk in hyperplasia without atypia. 
 The breast cancer risk associated with benign breast disease differs by 
menopausal status. Atypia in premenopausal women have higher relative risk of 
breast cancer than in post menopausal women.(30) 
Mammographic Density 
Mammographic density is a strong risk factor for breast cancer.  It represents 
connective and epithelial tissues in the breast ,whereas the dark radiolucent areas 
on the mammogram are primarily fat.  Women with  highest mammographic 
density are 4-6 times more likely to develop breast cancer  than very low 
density.(31) 
 
Ionizing Radiation 
Ionizing radiation is  has increased risk of breast cancer.Information on 
radiation and breast cancer risks    has come mainly from epidemiological studies 
of atomic bomb survivors or  women exposed to radiation for diagnostic or 
therapeutic reasons. Relative risks vary from 1.2 -2.4 and are related to both total 
dose and age at exposure. Younger women had greater risk than older women(32). 
The effect of very low doses such as those incurred in occupational exposures is 
uncertain .  Because of the low doses involved in screening mammography (200 – 
400 mrad) and of the finding that older women were less susceptible to ionizing 
radiation, the benefit risk ratio for older women would still be large . 
Socioeconomic Status 
Higher socioeconomic status  has a role in breast cancer .  Developed 
countries have much higher breast cancer rates than developing countries.  This 
correlation between socioeconomic status and breast cancer risk has also appeared 
at both the,individual and community level.The higher breast cancer risk among 
well-educated women appears to be attributable to greater exposure to breast 
cancer risk factors such as later age at first pregnancy, having few or no children, 
and more frequent use of oral  contraceptives and hormone therapy  
 RISK FACTORS FOR BREAST CANCER AND THEIR RELATIVE 
RISKS(33) 
S.No. RISK FACTOR COMPARISON 
CATEGORY 
RISK 
CATEGORY 
RELATIVE 
RISK 
1. Age at menarche 16 years Younger than 
12 years 
1.3 
2. Age at 
menopause 
45 to 54 years After 55 years 1.5 
3. Age at when first 
child born alive 
Before 20 yeats Nulliparous or 
older than 30 
years 
1.9 
4. Benign breast 
disease 
No biopsy or fine 
needle aspiration 
Any benign 
disease 
1.5 
Proliferative 
disease 
2.0 
Atypical 
hyperplasia 
4.0 
5. Family history  No 1st degree 
relative affected 
Mother 
affected 
1.7 
Two first 
degree 
relative 
affected 
5.0 
6. Obesity 10 th percentile 90th percentile 1.2 
7. Alcohol use Non drinker Moderate 
drinker 
1.7 
8. Estrogen 
replacement 
therapy 
Never used Current use 
>3 years 
1.5 
 
 
Diagnostic  modalaties  
Mammography  
Screening  mammography, is used to detect cancer in asymptomatic women. 
Diagnostic mammography is used to evaluate to 
1. Patients with breast symptoms or complaints,such as nipple discharge or a 
palpable mass 
2. Patient who  have had abnormal results on screening mammography or 
3. Patients who had under went  breast conservation therapy. 
The diagnostic examination is tailored to the individual patients specific 
abnormality . 
 
Digital mammography (Also called full-field digital mammography, or 
FFDM) –  
FFDM  is  anew technology that was recently approved by the FDA for 
breast cancer screening and diagnosis.  They capture the  images which are 
processed on a computer and then viewed. 
BI-RADS diagnostic categories — 
After analysing the mammographic images, radiologists classify findings 
into a final assessment category .The Breast Image Reporting And Data 
System(BIRADS) ,final assessment classification was developed by the American 
College of Radiology to standardize mammographic reporting. Follow up 
recommendation are made based on the final assessment category.BIRADS 0 or 
incomplete final assessment  require additional imaging to render or resolve, or 
define an abnormality on screening examinations. 
ULTRASONOGRAPHY  
Ultrasound can be used to differentiate between solid and cystic breast 
masses that are palpable or detected mammographically. In addition, ultrasound 
evaluation of the axilla can be used to detect lymph nodes that are suspicious for 
axillary metastases. Ultrasound provides guidance for interventional procedures of 
suspicious areas in the breast or axilla. 
BREAST MRI  
The sensitivity of MRI for breast carcinoma is between  88  and  100 
percent .Invasive breast cancer shows  contrast enhancement on MRI. Because 
MRI is so sensitive, it was assumed that preoperative MRI would estimate the 
extent of disease, more accurately than conventional imaging, thereby improving 
surgical planning (eg, prompting a change to mastectomy when breast conserving 
therapy had been previously considered and enabling surgeons to obtain clean 
margins in breast conserving surgery). 
Fine needle aspiration cytology 
FNAC of a palpable breast mass can easily proceed in outpatient setting.  
They are used to differentiate solid and cystic lesions. 
The combination of diagnostic mammography,ultrasound and fine needle 
aspiration biopsy achieves almost 100% accuracy in diagnosis of breast cancer. 
Biopsy 
Core Needle biopsy 
Core needle biopsy is, tissue sample obtained from the mass by using  
hollow needle. The advantages of core biopsy are low complication rate, avoidance 
of scarring and low cost 
Open biopsy 
An open biopsy is recommendedonly only in patients who have been 
appropriately investigated by imaging,FNAC,and or  by core needle biopsy 
 
Proliferative Biomarkers 
High proliferative decreases of breast cancer is  associated with favourable 
response to chemotherapy.The main obstacles to use proliferative markers are  
1.Poor standardisation of detection methods 
2.Vaguely defined cutoff values 
3.Requirement of fresh fozen tissue 
Proliferative biomarkers are 
1.Measurement of  cells in S phase: 
  Unfavourable prognosis  of breast cancer patients are seen when S 
phase fraction is assessed by fresh or frozen material . But several studies done to 
assess the prognostic value by DNA flow cytometry lacks standardised  
procedures,sufficient power and predifined cutoff values. There is also high 
tumour heterogenity of the S phase fraction .Therefore it cannot be recommended 
for routine prognositc assessment. Another disadvantage of this method is requires 
large quantity of tumour material, making it inappropriate for smaller tumours 
identified through mammographic screening. 
2.H-Thymidine Labeling Index 
 H-thymidine labeling index was one of the  proliferative  used in breast 
cancer. Cells undergoing DNA replication is  measured by H-thymidine uptake 
using autoradiography. Thymidine labeling index represents ratio between the 
number of labelled and counted cells .A similar approach uses IHC technique and 
halogenated analogue -Bromodeoxyuridine.Limitations of this technique are the 
requirement of fresh frozen tissue,the time requirerd to complete the assay and use 
of radioactive tracers. 
3.Thymidine Kinase  
Thymidine kinase activity is measured by radioenzymatic assay Thmidine kinase is 
an enzyme that catalyses the phosphorylation of deoxythmidine to 
deoxythymidinemonophosphate. Its activity is highest in G1-G translation check 
point and then reduced in G2  phase of cell cycle. In breast cancer ,the fetal 
isoform of Thymidine kinase is present in high levels in the cytoplasm and 
regulates the cell cycle. 
4.Ki67 
Ki 67 is a nuclear antigen which is present in mid G1,S,G2 and the entire M Phase  
of the cellcycle .Overexpression of Ki67 correlates with  proliferative activity 
metastases and overall survival. 
5.MIB1 
Similar to Ki67, MIB1 is  a nuclear antigen that can be labelled using 
immumohistochemistry. It can be performed on formalin fixed and paraffin 
embedded tissue. A good concordance is seen   between Ki67 and MIB1 
assessment. 
6.Cyclin A 
Cyclins are proteins that regulate cell cycle. Cyclin A is expressed mainly in the 
late S,G2 and M phases of the cell cycle. It has been associated with poor 
prognosis. 
7.Cyclin E 
Cyclin E regulates G1 phase progression and entry into S phase.There are two 
different proteins,cyclin E1 and E2.,that are coded by 2  different genes with 47% 
homology. Cyclin E1 is determined by immunohistochemistry ,western blot and 
RT-PCR.Elevated levels of cyclins  increases risk of breast cancer related death. 
8.Cyclin D1  
The family of cyclin D consists of atleast three different cyclins that regulate 
progression into G1 phase. The function of cyclin D1 is to bind to the cyclin 
dependent kinases 4 & 6 and phosphorylate downstream proteins .These 
complexes can sequester  cyclin D kinase inhibitors .Cyclin D1 acts as a cofactor 
for ER alpha in a ligand independent manner. The concentration of Cyclin D1 is 
the highest during mid G1 phase and then gradually declines. Overexpression of 
cyclin D1,mRNA,protein and amplification to be 15% in breast cancer.They are 
found to be associated withre ER positive and well differentiated tumours .The 
most common method of detection of cyclin D1 expression is 
immunohistochemistry. 
 9.p27 
p27 is a cyclin dependent kinase inhibitor that acts in the nucleus.It is mobilized by 
antiproliferative signals,such as cell to cell contact and transforming growth factor 
beta.It can be assessed by immunohistochemistry.In majority of the studies p27 
was positively correlated with ER expression and inverse correlation with the 
grade.In BRCA1/2 mutated tumours,low level of p27 are seen. 
10.Topoisomerase II alpha 
Topoisomerase II  are DNA binding enzymes with nuclease,helicase and ligase 
activity. Topoisomerase IIbeta is not cell cycle dependent  whereas topoisomerase 
IIalpha is cell cycle dependent and is highest inG2/M transition.Coamplification of 
topoisomerase II and Her-2  are associated with increased sensitivity to 
anthracyclines. It is also used as a prognostic marker  for overall survival of breast 
cancer patients independent of therapy 
11.Urokinase plasminogen activator(uPA) and Plasminogen activator 
inhibitor(PAI-1) 
uPA and PAI-1 levels are associated with breast cancer recurrence and 
survival.They also predict the hormone therapy and specific types of chemotherapy 
response. 
 The breast cancer markers that are most important in determining therapy 
are estrogen and progesterone receptor and Her-2/neu 
  
Staging of  breast cancer  
TNM staging of tumour is based on size of primary tumour,regional lymph 
node and distant metastasis. 
American Joint Committee on  Cancer (AJCC) staging system provides guidelines  
for  breast cancer patient according to the prognostic status.The AJCC has 
designed  staging by TNM classification.(34) 
TNM STAGING 
Primary tumour(T): 
TX:Primary tumour cannot be assessed 
T0:No evidence of primary tumour 
Tis:Carcinoma insitu;DCIS/LCIS/Pagets 
T1: Tumour size(2 cm or less). 
T1a:less than 0.1cm microinvasion  
T1b:more than 0.5cm but less than 1cm  
T1c:more than 1cm but less than 2 cm  
T2: Tumour size 2-5cm  
T3:Tumour size more than 5cm  
T4:Tumour of any size with direct extension to chest wall and or to the 
skin(ulceration or skin nodules) 
T4a:Extension to chest wall,not including only pectoralis muscle 
invasion/adherence 
T4b:Ulceration and/or ipsilateral satellite skin nodules and/or edema ) 
T4c:both of the above(T4a and T4b) 
T4d:Inflammatory carcinoma 
Regional lymph nodes(N) 
NX:  (RLN) cannot be assessed 
N0: No regional lymphnode metastasis 
pN0(i-): No ‘RLN’ metastasis identified histologically, negative IHC 
pN0(i+):Malignant cells in ‘RLN’ less than 0.2 mm (detected by H&E or IHC) 
pN0(mol-):No RLN metastasis histologically, negative molecular findings(RT-
PCR) 
pN0:Positive molecular findings (RT-PCR) but no RLN metastasis detected 
histologically or by IHC 
pN1:Micrometastasis: or metastasis to 1 to 3 axillary lymphnodes and/or internal 
mammary nodes with metastases detected by sentinel lymph node biopsy but not 
clinically detected 
pN1m1:Micrometastasis(greater than 0.2 mm and /or more than 200 cells but none 
greater than 2.0mm) 
pN1a:Metastases in 1 to 3 axillary lymphnodes,atleast one metastases greater than 
2.0 mm 
pN1b:Metastases in internal mammary nodes with micrometastases or 
macrometastases detected by sentinel lymph node biopsy but not detected 
clinically 
pN1c:Metastases in 1 to 3 lymph nodes and in internal mammary nodes with 
micrometastases or macrometastases detected by sentinel lymph node biopsy but 
not detected clinically 
pN2:Metastases in 4-9 axillary lymph nodes; or in clinically detected** internal 
mammary nodes in the absence of axillary lymph node metastases 
pN2a:Metastases in 4-9 axillary lymph nodes(atleast one tumour deposit greater 
than 2.0 mm). 
pN2b:Metastases in clinically detected internal mammary nodes and in the absence 
of axillary LN metastasis 
pN3:Metastases in 10 or more axillary lymph nodes;or in infraclavicular (level3) 
lymph nodes;or in clincally detected ipsilateral internal mammary in the presence 
of 1 or more positive level 1,2 axillary lymph nodes;or, in more 
pN3:Metastases in 10 or more axillary lymph nodes;or in infraclavicular (level3) 
lymph nodes;or in clincally detected ipsilateral internal mammary in the presence 
of 1 or more positive level 1,2 axillary lymph nodes;or, in more than 3 axillary 
lymph nodes and in internal mammary lymph nodes with micrometastases or 
macrometastases detected by sentinel lymph node biopsy but not clinically 
detected or in ipsilateral supraclavicular lymph nodes 
pN3a: Metastases in 10 or more axillay lymph nodes(at least one tumour deposit 
greater than 2.0mm);or metastases to the infraclavicular (level3 acillary lymph 
nodes and in internal mammary lymph nodes) nodes 
pN3b:Metastases in clinically detected ipsilateral internal mammary lymph nodes 
Distant metastases(M): 
MX: metastasis cannot be assessed 
M0:No distant metastasis 
M1:Distant metastasis present (includes metastasis to ipsilateral supraclavicular 
lymph nodes) age groupings 
 
 
 
 
 
STAGING: 
Stage groupings: 
Stage 0 
 Tis,N0,M0 
Stage 1 
 T*1,N0,M0  
*T1 include T1mic 
Stage 2A 
 T0,N1,M0 
 T1*,N1**,M0 
 T2,N0,M0 
 *T1 includes Tmic 
.**The prognosis of patient with pN1a 
disease is similar to that of pN0 disease 
Stage 2B 
 T2,N1,M0 
 T3,N0,M0 
Stage 3A 
 T0,N2,M0 
 T1*,N2,M0 
 T2,N2,MO 
 T3,N1,M0 
 T3,N2,M0 
 *T1 includes T1 mic 
Stage 3b 
 T4,Any N,M0 
 Any T,N3,M0 
Stage 4 
 Any T,Any N,M1 
 
 
Histological Grading of Breast Cancer 
 
Histologic grading based on 
1. Cell mitosis 
2. Tubule formation 
3. Nuclear pleomorphism 
 
 
 
 
 
  
 
 
 
 
 
 
The grading criteria are as follows: 
Modified Bloom Richardson  histologic scoring criteria(35) 
1.Tubule formation 
>75% 
10 to 75% 
<10% 
2. Nuclear pleomorphism 
 
Small uniform cells                                                     
 
Moderate increase in size and variation 
 
Marked variation 
3.Number of Mitosis (Microscope Nikon 40x objective) 
 
Upto 5 
 
6-10 
 
Score 
1 
2 
3 
 
 
1 
 
2 
3 
 
 
1 
 
2 
 
3 
More than 11 
 
 
 
Nottingham Modification of Bloom Richardson grading system: 
GRADE DESCRIPTION  SCORE 
Grade 1 Well differentiated breast cells. 
Cells generally appear normal.not growing rapidly. Cells 
arranged in small tubules. 
3,4,5 
Grade 2 Moderately differentiated breast cells.Have characteristics 
between Grade 1 & 3 tumours 
6,7 
Grade 3 Poorly differentiated breast cells.Cells do  not appear 
normal and tend to grow and spread aggressively. 
8,9 
 
 
 
 
 
 
 
 
FIVE YEAR SURVIVAL RATE: 
STAGE 5YEAR SURVIVAL RATE 
0 100% 
I 100% 
IIA 92% 
IIIB 81% 
IIIA 67% 
IIIB 54% 
IV 20% 
 
 Estrogen receptor 
Estrogen receptors are members of the steroid receptor superfamily. Two 
isoforms of ER such as ER alpha and ER beta have been identified. Although ER 
alpha and ER beta have only 30% overall sequence similarity,their DNA binding 
and ligand binding domains are highly homologous ,suggesting that the two 
receptors likely share similar ligands and DNA binding activity. Most of the 
knowledge about ER activity and function has been obtained from studies on ER 
alpha. Much less is known about ER beta(36). 
The ER is a nuclear transcription factor that regulates the expression of 
,number of genes involved in regulation of transcription and differentiation. 
Binding of ligand to ER results in a ligand-ER complex that subsequently induces 
an ER conformational change,dissociation of chapreones such as hsp90 and hsp70 
and receptor dimerisation.Activated ER dimers can bind to the Estrogen receptor 
elements(ERE) of target genes and regulate their transcription. Some nuclear 
proteins interact with ER and function as coactivators or corexpressors of ER. 
 
Because of the pivotal role that ER plays in breast cancer progression, 
development of specific agents, targeting ER or its ligands has become an 
important strategy for breast cancer treatment. Applied endocrine therapies, 
include depletion of the ligand ,estrogen ,steroidal antiestrogens that destroy ER 
and selective ER modulators. 
Unfortunately denovo or acquired hormone resistance is  a feature of some 
breast cancers. Approximately 30% of breast cancers lack ER gene expression. 
Tumour lacking ER protein are usually associated with higher growth rate, poor 
differentiation and worse clinical outcome. Thus ER expression has been a 
possible prognostic factor for early breast cancer patients. Genetic changes  that 
account for the loss of ER in breast cancer include deletions, insertions ,point 
mutations or rearrangement of ER gene. 
ER alpha which is located on chromosome 6q25.1, contains 595 aminoacids 
with central DNA binding domain with carboxy terminal hormone binding 
domain.ER beta which is located on chromosome 14q23.2 ,lacks large portion of 
carboxy terminal F domain. 
 Tissue distribution of ERs: 
The distribution of two receptors overlap in breast, endometrium, bone, 
prostate, epididymis, central  and peripheral nervous system(37). 
Liver and white adipose tissue show ER alpha expression alone. 
Kidney,Bladder,Intestine ,ovary and show only ER beta expression alone. 
ER alpha gene polymorphism that are studied  frequently are Pvull and Xbal 
gene polhymorphism .They have been associated with breast cancer,prostate 
cancer ,neurodegenerative disorder such as Alzheimers disease . 
Screening for intron 1 single nucleotide polymorphism in ER alph gene is 
commonly carried out by means of PCR amplification followed by RFLP analysis. 
Pvull is used for T397C and XbaI is usedfor C351G.PCR is utilized to amplify TA 
dinucleotide repeat using labelled -deoxy cytidine triphosphate(38).Amplified 
products are then seprated and analysed on denaturing polyacrimide sequencing 
gel. 
 
 
 
  
 
 
 
 
 
 
IMMUNOHISTOCHEMISTRY 
 
 IMMUNOHISTOCHEMISTRY 
Immunohistochemistry involves two disciplines immunology and 
histology.Immunohistochemistry is used to determine expression of particular 
antigen and its microanatomic location in the tissue. 
 Immunohistochemistry was started in 1940 when Coons developed an 
immunofluorescence technique to detect corresponding antigen in frozen sections. 
Taylor and collegues in 1974 showed it was possible to demonstrate antigens 
in routinely processed tissue.Antigen retrival technique was introduced by Shi and 
associates in 1991.Antigen retrival technique is  a simple method that involves 
paraffin processed sections at high temperature before IHC staining. 
The use of antibody in IHC depends on the sensitivity and specificity of the 
antigen –antibody reaction. 
Blocking non-specific background staining 
  Background staining is due to either non specific binding or presence of 
endogenous enzymes.Non specific binding with polyclonal primary antibody is 
minimized by preincubating sections with serum from same species on optimal 
working dilution. 
Endogenous enzymes such as peroxidase seen in normal and neoplastic 
tissues is abolished by peroxidase blocking or by using alternate systems such as 
immunogold technique. 
Methods suggested to overcome endogenous activity include incubation in 
methanol containing 0.5% hydrogen peroxide for 10 minutes at room 
temperature(almost complete abolition of endogenous peroxidase 
activity).Endogenous alkaline phosphatase is blocked by addition of 0.1M 
concentration of levamisole to the enzyme substrate solution. 
Detection systems: 
 Antibodies are labeled or flagged by some method to permit visualization 
.These includes fluorescent substances, enzymes forming colored reaction with 
suitable substrate(light microscopy) or heavy metals(electron microscopy) 
 Methods of IHC: 
Direct labeling method: 
 Antibody is attached with a label by chemical means and directly applied to 
tissue sections. It is a rapid and easy procedure and carries the disadvantage of 
usinf  multiple antigens which require seprate incubation with respective 
antibodies. 
Indirect labeling method: 
 Enzymes are labeled with secondary antibody ,which is produced against 
primary antibody. This method is more sensitive and easy to handle. The 
advantages also include increased versatality ,higher working dilution of primary 
antibody, secondary antibodies against primary antibody of different species and 
easy to prepare. 
Avidin biotin techniques: 
 High affinity binding between biotin and avidin is used in this 
procedure.Biotin is chemically linked to primary antibody and avidin is conjugated 
chemically to enzyme.The avidin binds to biotinylated antibody thus localizing the 
peroxidase moiety at the site of antigen. 
 Disadvantages of this technique is that, the endogenous biotin produces non 
specific background staining. 
Avidin biotin conjugate procedure: 
 In this technique primary antibody is added followed by biotinylated 
secondary antibody and next by preformed complexes of avidin and biotin horse 
raddish peroxidase conjugate.This is a more sensitive method. 
Biotin streptavidin system: 
 Streptavidin is used in place of avidin. Streptavidin complexes are more 
stable. 
Immunogold silver stain technique: 
 This is used in ultrastructural immunolocalisation.Gold particles are 
enhanced by the addition of several layers of metallic silver.The fine silver 
deposits in the background  & create confusion when small amounts of antigen are 
identified. 
Polymeric method: 
 This technique permits binding of large number of enzyme molecules to a 
secondary antibody via the dextran backbone. Advantages of this technique are 
increased sensitivity, minimized non specific background staining and a reduction 
of total number of assay steps. 
Tissue fixation,processing and antigen retrival techniques: 
Tissues for IHC undergo fixation,dehydration and paraffin embedding. 
Fixation 
This is a critical step, as the preservation of morphology is essential for 
interpretation of IHC.10% buffered formalin is commonly used because of the 
following advantages. 
1. Good morphological preservation 
2. Cheap 
3. Sterilize tissues 
4. Carbohydrate antigens are better preserved. 
The disadvantage of masking of antigens during fixation can be overcome 
by antigen retrivel techniques. 
Antigen Retrievel: 
This procedure involves unmasking of the antigens.Following techniques 
can be used. 
1. Proteolytic enzyme digestion 
2. Microwave antigen retrivel 
3. Microwave and trypsin and antigen retrieval technique. 
4. Pressure cooker antigen retrieval. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
MATERIALS AND METHODS 
 
 
 
 MATERIALS AND METHODS 
The study was done during the period,June 2010-September 2012.It was 
carried in two groups, namely, apparently healthy female controls and patients  
with confirmed diagnosis of carcinoma breast.The study was approved by ethical 
committee of Stanley Medical College. 
STUDY POPULATION 
CASES 
The study sample comprised of 153 breast cancer patients. Cases were 
chosen from Department of surgey, medical oncology and radiotherapy, Stanley 
Medical College and Hospital. Clinical history such as size of tumour ,presence of 
axillary lymphnodes, metastasis, stage and type of breast cancer  was also 
collected.75 patients were screened for receptor status of estrogen through 
immunohistochemical assay. 
CONTROL SUBJECTS 
 Controls were recruited from outpatient clinic during their visit in 
gyneacological  department. Healthy ,age-matched women ,without a family 
history of breast cancer or any other cancers,were selected to serve as control 
group.The study sample comprised of 150 controls  
Subjects with amenorrhea ,hormonal disorders,any systemic disease like 
diabetes mellitus,cardiovascular diseases were excluded from both groups.estrogen 
receptor alpha gene polymorphism was detected using polymerase chain reaction. 
METHOD OF DATA COLLECTION  
153 cases were studied and out of these 153 cases 75 cases is selected at 
random for doing  estrogen receptor immunohistochemistry .The tissues so 
obtained were processed and sections were cut at   5microns. Hematoxylin and 
eosin staining of the sections were done  and studied . 
For both the cases and control ER alpha genotype frequency was done by 
PCR by collecting 5 ml of venous blood. Also random blood sugar was estimated 
for both cases and control. Height and weight was recorded. 
  
 
 
METHOD OF TISSUE PREPARATION OF IHC 
10% buffered formalin was used for fixing the specimens .The tissues were 
processed in various grades of alcohol and xylol using automated 
histokinette.Paraffin blocks were prepared and section of  5 micron thickness were 
cut in semiautomatic microtome using disposable blades and stained with 
hematoxylin and eosin.Suitable blocks were chosen for IHC. 
Sections for immunohistochemistry were also cut in semiautomatic 
microtome using disposable blades.Slides  coated with chrome alum were 
used.Sections were subjected to antigen retrival using microwave technique using 
TRIS EDTA(ph 9.2) buffer solution and then treated by HPR( horse radish 
peroxidase) polymer technique. 
HRP POLYMER TECHNIQUE 
The coated slides were taken through the following stages  
1. Treatement with peroxidase block –for inhibiting endogenous peroxidases in 
the tissue for 20 minutes 
 
2. Wash with TRIS buffer for 5 minutes  
3. Application of power block –blocks non specific antigen antibody reaction-
20 minutes 
4. Blot dry the excess power block  
5. Application of primary antibody for 60 minutes 
6. Wash in TRIS buffer for 5 minute thrice 
7. Application of superenhancer  for 30 minutes which enhances the final 
reaction product by increasing the sensitivity of antigen antibody reaction. 
8. Application of SS label –secondary antibody from the goat with the tagged 
horse radish peroxidase  enzyme for 30 minutes 
9. Wash thrice in  TRIS buffer 
10. Application of DAB (Diaminobenzidine ) chromogen for 5 minutes –this is 
cleaved by the enzyme to give the coloured product at the antigen sites 
11. Wash in distilled water for 5 minutes 
12. The slides were counterstained with hematoxylin 
13. Air dried and mounted with DPX(Distrene diputyl pthalide in Xylol) 
 
METHOD OF SCORING FOR ER (36) 
Q SCORE 
Score for intensity  
0-No staining  
1-Weak staining 
2- Moderate staining 
3-strong staining 
Score for proportion of positivity  
0-No staining 
1-<1% of nuclei staining  
2-1%-10% of nuclei staining  
3-11%-33% of nuclei staining  
4-33% -66% of nuclei staining  
5-67%-100% of nuclei staining  
  The scores were summed to give a maximum score of 8.Scores 2 or less are 
regarded as ER negative. 
Sample collection  for ER alpha gene polymorphism : 
5ml of peripheral venous blood was withdrawn under sterile conditions with 
disposable syringes from all the cases and controls of this study, and transferred to 
EDTA tube and mixed thoroughly.EDTA tube was centrifuged at 2000rpm for 
twenty minutes to get the buffy coat for DNA extraction. 
BUFFY COAT PREPARATION 
  Buffy coat was separated by centrifugation of EDTA tubes at 2000 
revolution for 20 minutes.Buffy coat was transferred to 2ml eppendorf and was 
used for DNA extraction.DNA extraction of some samples were done by chemical 
method  
DNA EXTRACTION BY MODIFIED HIGH SALT METHOD 
RBC LYSIS  
1.400µL of buffy coat in a 2ml eppendorf was mixed with 1.6ml of 0.17M 
ammonium chloride and mixed by inversion until red cells are lysed for about 10 
minutes 
 
2.The cells were centrifuged at 4000rpm for 10 minutes 
3.The white pellet  was washed with 800µL of 0.17M ammonium chloride 
solution .The procedure was repeated till a clear white cell pellet was obtained 
WBC LYSIS 
To the pellet 500µL of TKM I solution was added .It was centrifuged at 
10,000 rpm for 10 minutes  
NUCLEAR LYSIS  
1.Supernatant was discarded.To the pellet 500µL of TKMII solution was 
added. 300µL of 6M  Nacl and 50µL of 10% SDS was then added. 
2.The solution was mixed well & centrifuged at 10000rpm for 10 minutes. 
3.Supernatant .was transferred  to 1.5ml eppendorf 
DNA  precipitation  
1.To the supernatant double the volume of 100% ethanol was added  
2.The sample was stored at -20*c for 1 hour 
3.Then it was centrifuged at 10,000rpm for 2 minutes at 4*C in a 
refrigerated centrifuge. 
4.The supernatant was discarded.To this 500µL of 70%  ethanol was added 
.The pellet was mixed and centrifuged at 10,000rpm for 10 minutes at 4*C. 
5.Supernatant was discarded and the pellet is air dried 
STORAGE 
To the pellet 30µL OF LTE buffer is added and the extracted DNA is stored at-
20*C for future use. 
IDENTIFICATION: 
Extracted DNA was identified by 1% agarose gel electrophoresis and 
comparison with  a known molecular weight 1 kb DNA ladder  
 
 
 
POLYMERASE CHAIN REACTION: 
1300 bp fragment of ESR 1 gene was amplified using Forward primer-
TTAGAAAAGCAAAACATGCACTC 
Reverse primer-GCCACCCTATCTGTATCTTTTCC(from Helini 
Biomolecules,Chennai) 
Primer Reconstitution: 
 Primers are supplied in lyophilized form. Autoclaved distilled water was 
used to prepare 100x concentrations i.e..10 times the molecular weight of primer 
was the volume of water required to prepare 100x concentrations which is 100µ 
molar solution. 
 From this stock solution 10x concentration was prepared as per the working 
solution for PCR. 
MASTER MIX: 
Master mix consist of basic components necessary for PCR 
• Reaction buffer consisted of TrisHcl-10mM at pH 8.3 KCL-50mM. 
• MgCL2-1.5mM acts as catalyst 
• dNTP’s were used in a concentration of 2.5mM each. 
• Taq polymerase in a concentration of 1.5U 
Primers were used in a concentration of 10pmol and DNA was used in a 
concentration of 200ng. 
PCR was carried out in a reaction volume of 25µL with the following 
components. 
PCR master mix-12.5 µL 
Forward primer-1.0 µL  
Reverse pimer-1.0 µL 
DNA-1.0 µL 
Distilled water-9.5 µL 
Total-25 µL 
Amplification was carried out in an Applied Biosystems thermal cycler with 
the following cycling conditions. 
 Initial denaturation-94°C-5 min 
 30 cycles of  
 Denaturation-94°C-30 sec 
 Annealing-55°C-1min 
 Extension-72°C-1 min 30sec 
 Final extension at 72°C-5 min 
 
Amplified product –amplicons of 1300bp was identified by 2% agarose gel 
electrophoresis by comparison with  a known 100bp DNA ladder 
AGAROSE GEL ELECTROPHORESIS 
• PCR product was run on 2.0% agarose gel in a 30 mL agarose cast as 
follows:0.60g of agarose was weighed and dissolved in 30mL of TAE bufffe 
with a pH of 8.0 
• It was microwaved for 60secs,cooled and 1.5 µL of ethidium 
bromide(10mg/ml) is added .It is poures into a cast and allowed to solidify 
for 15 min before it is kept in the electrophoresis tank. 
• 10 µL of PCR product is loaded onto wells and 10 µL of 100bp DNA ladder 
is loaded onto single well as a marker.It is electrophoresed for 30 minand 
visulaised under UV illumination. 
 
RESTRICTION DIGESTION OF PCR PRODUCTS 
 
 ESR1 polymorphism was detected by digestion of the PCR amplified 
product with Pvull restriction enzyme followed by run in 2% agarose gel 
electrophoresis. 
 Principle of Pvull enzyme digestion  
• P allele does not have the restriction site hence will yield  a 1300bp 
fragment 
• p allele has the restriction site,hence gets cleaved to give 864bp and 
436bp fragments. 
• Heterozygous individuals (Pp) have 1300bp,864bp,436bp fragments. 
• Analysis was done using a 100bp DNA ladder. 
Procedure: 
• 10 µL of PCR product is aliquoted to an eppendorf and 1U of Pvull enzyme 
is added.The entire procedure is carried out in ice.The contents are mixed 
thoroughly. 
• The eppendorf is then placed in 37°C waterbath for 2 hours and reaction is 
stopped by adding 5 µL of gel loading dye and mixed thoroughly. 
• Restriction digested product is subjected to 2.5% agarose gel electrophoresis 
for genotyping. 
 STATISTICAL ANALYSIS  
1. Allele frequencies were calculated by allele counting. 
2. Genotype frequency distribution between cases and controls were compared 
with x² test for 2x2 contigency table 
3. Association between ER alpha genotype and ER status is compared with 
Fischer’s Extract test. 
4. Odd’s ratio was calculated to know the correlation of stage of tumour,BMI 
with genotype distribution. 
5. Age and blood sugar levels are compared between control subjects and 
patients by student t test. 
  
 
 
 
 
 
 
 
OBSERVATION AND RESULTS 
  
RESULTS 
153 breast cancer patients and healthy controls were analysed for genotype 
distribution of Pvll polymorphism of the ERαgene. The genotype distribution was 
studied with respect to risk confounding factors such as menopausal status ,stage of 
the tumour and BMI.75 patients were studied with respect to estrogen receptor 
status.The results found are as follows: 
 TABLE 1:Genotype distribution  of ER α    GENE in breast cancer patients 
and controls 
  PP 
n(%) 
Pp 
n(%) 
pp 
n(%) 
Patients 
153 
52 
(34%) 
66 
(43.1%) 
35 
(22.9%) 
Control 
150 
32 
(21.3%) 
76 
(50.7%) 
42 
(28%) 
  
X²=6.07 
p<0.05 
OR for  PP Vs Pp-1.87(CI-1.08<OR<3.24) 
PP Vs pp-1.95(CI-1.04<OR<3.66) 
Pp Vs pp-1.04(CI-0.59<OR<1.82) 
The allele frequencies were PP=84,Pp=142,pp=77.this is found to be in hardy 
Weinberg equilibrium , -1.17,pvalue is 0.28 
  
PP genotype was more frequent among cases(34%) when compared to controls 
(21.3%) with  x² value 6.07 and p value<0.28. 
  
TABLE 2:  Pvull polymorphism of ER alpha gene and Estrogen receptor 
status in breast cancer patients: 
 
   Total PP Pp pp 
ER POSITIVE 45 20 
(44.4%) 
23 
(51.1%) 
2 
(4.4%) 
ER NEGATIVE 30 6 
(20%) 
15 
(50%) 
9 
(30%) 
  
Fisher’s Exact test=10.78 
p<0.01  
OR for  PP Vs Pp-2.17(CI-0.70<OR<6.66) 
PP Vs pp-15.00(CI-2.52<OR<89.23) 
Pp Vs pp-6.90(CI-1.30<OR<36.45) 
 Table shows the frequency of PP genotype was elevted in patients positive for 
ER(44.4%) as compared to those who were ER negative(23.7%). The OR for 
genotype PP Vs pp was  15(CI-2.52<OR<89.23). 
 
 
TABLE 3:Pvull polymorphism  of ER α gene and Menopausal status  in 
breast cancer patients 
  PP 
n(%) 
Pp 
n(%) 
pp 
n(%) 
Premenopausal 
n=79 
33 
(41.8%) 
35 
(44.3%) 
11 
(13.9%) 
Control 
N=74 
19 
(25.7%) 
31 
(41.9%) 
24 
(32.4%) 
                                
X²=8.68 
p<0.05 
OR for  PP Vs Pp-1.54(CI-0.73<OR<3.23) 
PP Vs pp-2.46(CI-1.04<OR<5.83) 
Pp Vs pp-3.79(CI-1.53<OR<9.41) 
Premenopausal women had elevated frequency of PP genotype(41.8%) as 
compared to postmenopausal women (25.7%) with x²-8.69,p<0.05. the OR for 
genotype PP Vs pp was 3.79(95% CI-1.53 to 9.41).The OR for genotype Pp Vs pp 
was 2.46(95% CI -1.04 to 5.83) 
   
 
 TABLE:4 Pvull polymorphism  of ER αGENE and stage of breast cancer 
patients 
  PP 
n(%) 
Pp 
n(%) 
pp 
n(%) 
Early satge 1&2 
n=84 
38 
(42.2%) 
36 
(42.9%) 
10 
(11.9%) 
Advanced stagel 
N=69 
14 
(20.3%) 
30 
(43.5%) 
25 
(36.2%) 
                                
X²=16.74 
p<0.01 
OR for  PP Vs Pp-2.26(CI-1.04<OR<4.94) 
Pp Vs pp-3 (CI-1.25<OR<7.23) 
PP Vs pp-6.79 (CI-2.61<OR<17.7) 
pp genotype was  significantly elevated in advanced stage breast cancer(36.2%) 
when compared to patients with early stage (11.9%).PP genotype frequency was 
significantly elevated in early stage (42.2%) as compared with advanced 
stage(20.3%). With X²=16.74 p<0.01.The OR for genotype Pp Vs pp-6.79 
(95%CI-2.61<OR<17.7).The OR for genotype PP Vs pp-3 (95% CI-
1.25<OR<7.23).The OR for genotype   PP Vs Pp-2.26(95% CI-1.04<OR<4.94) 
TABLE:5- Pvull polymorphism  of ER αGENE and BMI in  breast cancer 
patients 
  PP 
n(%) 
Pp 
n(%) 
pp 
n(%) 
BMI<30 
n=81 
31 
(38.3%) 
34 
(41.9%) 
16 
(19.8%) 
BMI>30 
N=72 
21 
(29.2%) 
32 
(44.4%) 
19 
(26.4%) 
                                
X²=1.72 
p>0.05 
OR for PP Vs Pp-1.39(CI-0.67<OR<2.89) 
PP Vs pp-1.75 (CI-0.74<OR<4.17) 
Pp Vs pp-1.26 (CI-0.55<OR<2.87)  
It was found that there was no significant difference in genotype distribution 
among obese and non obese cases (x²-1.71,p>0.05) 
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FIGURE :  1  Modified Radical mastectomy C/S -4x3cm grayish white firm mass in the lower outer 
quadrant 
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FIGURE :  2 Modified Radical Mastectomy.C/S-3x3cms grey white firm growth in lower quadrant 
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FIGURE: 3 H &E –Infiltrating Ductal Carcinoma NST -10X 
 
 
 FIGURE: 4 H & E – Infiltrating ductal carcinoma NST-10X 
 
 
 
 
 
 FIGURE: 5  INVASIVE DUCTAL CARCINOMA SHOWING ER POSITIVITY -10X 
 
FIGURE: 6 INVASIVE DUCTAL CARCINOMA NST SHOWING ER POSITIVITY-10X 
 
  FIGURE:   7 INFILTRATING DUCTAL CARCINOMA NST SHOWING ER NEGATIVITY-10X 
 
FIGURE: 8 INFILTRATING DUCTAL CARCINOMA NST SHOWING ER POSITIVITY-40X 
 
 
FIGURE:  9  INFILTRATING DUCTAL CARCINOMA NST SHOWING ER NEGATIVITY-40X 
 
 
 
 
 
 
 
 
  
 
  FIGURE: 10   EXTRACTED DNA 
  
 
 
FIGURE: 12   PCR PRODUCT 
  
FIGURE: 11 RESTRICTION DIGESTION FRAGMENTS 
 
  
 
 
 
 
 
 
DISCUSSION 
  
DISCUSSION 
 
 The present study was attempted to evaluate the role of ER alpha Pvull gene 
polymorphism in the breast cancer development. 
  
 The ER alpha gene comprises more than 140kb and has 8 exons and 5 
functional domains designated A/B-F. Several  sequence variations or single 
nucleotide polymorphism(SNPs) in ER alpha gene have been identified and found 
to be associated with either an increased or decreased risk of various diseases(39). 
The most widely studied polymorphisms of ER alpha were Pvull(T397C) and 
Xba1(A 351 G) located in intron 1. 
  Pvull gene polymorphism was studied in various diseases process of various 
organs. In view of this comprehensive population based study is performed to 
know the association of ER-α genotype in breast cancer patients. 
TABLE-6:Genotype distribution of ER –α gene in breast cancer patient and 
controls: 
Pvull gene 
polymorphism 
Surekha.D et al 
2007 
  
Daehee kang et al 
2002 
Present study 
 Cases 
n=249  
Control 
n=248 
Cases 
n=201 
Control 
n=195 
Cases 
n=153 
Control 
n=150 
PP 
n(%) 
88(35.3) 49(19.8) 35(17.5) 26(13.3) 52(34) 32(21.3) 
Pp 
n(%) 
93(37.3) 103(41.5
) 
91(45.3) 105(53.9) 66(43.1) 76(50.7) 
pp 
n(%) 
68(27.3) 68(27.3) 75(37.3) 64(32.8) 35(22.9) 42(28) 
 
 
Table  show the Pvull genotype frequency of the ER-α gene in both breast cancer 
cases and controls. 
According to the study conducted by Surekha.Det al  at Nizams instituite of 
medical sciences,Hydrebad ,India, (40) PP  genotype show increased  asssociation 
in breast cancer cases(35.3%) as compared to controls(19.8%). 
According to the results obtained in the present  study,the  frequency of PP 
genotype(34%) show  statistically   significant association  in breast cancer cases 
as compared to controls(21.3%) 
In this respect,the present study was consistent with the cited article.this could be 
because of similar patient profiles shared by both hospital. 
According to the study conducted by Daehee kang et al,2002,Seoul national 
university college of medicine,Korea(41),PP and pp genotype frequency was 
elevated  in breast cancer cases than in controls. It could be explained due to 
different   demographic profile.  
Sonia .M.boyapati et al ,2005 (42) study on breast cancer survival  indicate that 
there is no association between ER-α genotypes and breast cancer risk in a 
population based study in Shangai. 
 
Hence PP genotype was elevated in cases, hence that this genotype confers risk of 
breast cancer in our demographic profile 
 
 
 
TABLE 7:.Pvull polymorphism of ER-α gene and Estrogen  receptor status in 
breast cancer patients 
 
 Surekha.d et al Present study 
ER 
Status 
ER 
positive 
n=89 
ER 
negative 
n=97 
ER 
positive 
n=45 
ER 
negative 
n=30 
PP     
n(%) 
21(23.6) 17(17.5) 20 
(44.4%) 
6 
(20%) 
Pp 
n(%) 
38(42.7) 43(44.3) 23(51.1%) 15(50%) 
pp 
n(%) 
30(33.7) 37(38.1) 2(4.4%) 9(30%) 
 
In the reference article by Surekha.D et al (40) cited the PP genotype (23.6% 
Vs21%)  was increased in ER positive cases .But the statistical difference in Pp 
genotype status in both cases and controls are small percentage in both study. 
Hence this difference of  both PP and Pp association may be attributed to the 
difference in number of cases. PP genotype was the predominant  genotype in 
estrogen receptor positive cases. 
In the present study the PP  (44.4%)and Pp(51.1%) genotype was increasingly 
associated with ER positive cases than  ER negative cases with PP     
(20%),Pp(50%)genotype 
 Sonia .M.boyapati et al ,2005(42) study on breast cancer survival also found there 
is no variation of genotype according to the ER/PR status. 
The  present study also revealed the pp genotype was increasingly associated with 
ER negative cases (30%) than in ER positive cases(4.4%)i.In the surekha.D et al  
study also revelaed the pp genotype frequency is more in ER negative(38.1%) than 
ER positive cases(33.7%). 
 
 
 
 
 
 
TABLE 8:Pvull polymorphism of ER-α gene and menopausal status in breast 
cancer patients: 
 Surekha.d et al Present study 
 Pre menopausal 
n=123 
Post 
Menopausal 
n=125 
Premenopausal 
n=79 
Postmenopausal 
n=74 
PP 
n(%) 
28(22.8) 21(16.8) 33(41.8%) 19(25.7%) 
Pp 
n(%) 
48(39) 55(44) 35(44.3%) 31(41.9%) 
pp 
n(%) 
47(38.2) 49(39.2) 11(13.9%) 24(32.4%) 
 
In the study conducted by surekha.d et al(40) also PP genotype frequency 
was elevated in premenopausal women(22.8%)  than in post menopausal 
women(16.8%).Hence we can conclude PP genotype was the  risk factor in 
premenopausal women for breast cancer development. 
In the present study,the premenopausal women had elevated frequency of PP 
genotype(41.8%) as compared to postmenopausal women(25.7%). 
Kok HS,Van Asselt KM et al(43) ,in their study had suggested that ER-α gene 
polymorphism in particular,Pvull ,may affect the age of menopause. 
Wee AE et al(44) ,in their study suggested that P allele showed a dose effect 
relationship with a 0.5 year earlier onset of natural menopause per each copy of the 
P allele  
 Pvull polymorphism of ER-α gene and stage of breast cancer 
In the present study pp genotype frequencies was significantly elevated in 
advanced stage breast cancer(36.2%) when compared to patients with early stage 
(11.9%). 
Iin the study conducted by surekha et al(40) also the Pp and pp genotype 
frequency were found to be increased in patient with large tumour size and 
advanced stage of disease.Hence the presence of p allele frequency elevated in 
advanced stage disease may confer that the presence of p allele might confer a risk 
for an aggressive form of disease. 
 
 
Pvull polymorphism of ER-α gene and BMI in breast cancer patients: 
In the present study there was no significant difference in genotype 
distribution among the obese and non obese cases. 
Surekha.d et al study(40) has concluded that P allele frequency was elevated 
in overweight and obese patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
SUMMARY AND CONCLUSION 
 CONCLUSION 
 
1. From our study ,we conclude that PP genotype may be an independent risk 
factor for the development of breast cancer. 
 
2. It can also be concluded that pp genotype may be associated with ER 
negative tumour status and therefore leading to aggressive form of tumour. 
 
3. There was  no association seen between ER alpha genotype and and BMI. 
 
 
 
 
 
   
 
 SCOPE FOR FURTHER STUDY 
• Research  aimed identifying the association of  familial forms of breast  
cancer with Pvull allele and whether  it  may be included  as a germline risk 
factor for familial forms of breastcancer 
 
• Further research may be focused upon the hormone levels and its 
relationship with genotypic variation in patients with breast cancer,so as to 
provide efficient preventive measures to genetically susceptible population 
in future. 
 
 
 
 
 
 
  
 
 
 
ANNEXURES 
HO histologic  Classification of 
tumours of breast  
Epithelial tumours 
Invasive ductal carcinoma, not 
otherwise specified  
Mixed type carcinoma 
Pleomorphic carcinoma  
Carcinoma with osteoclastic  
giant cells  
Carcinoma with 
choriocarcinomatous features 
Carcinoma with melanotic 
features 
Invasive lobular carcinoma  
Tubular carcinoma  
Invasive cribriform carcinoma 
Medullary carcinoma  
Mucinous carcinoma and other 
tumours with abundant mucin 
Mucinous carcinoma  
Cystadenocarcinoma and 
columnar cell mucinous carcinoma  
Signet ring cell carcinoma  
Neuroendocrine tumours 
Solid neuroendocrine 
Atypical carcinoid tumour  
Small cell / oat cell carcinoma  
Large cell neuroendocrine 
carcinoma  
Invasive papillary carcinoma  
Invasive micropapillary carcinoma  
Apocrine carcinoma  
Metaplastic carcinomas  
Pure epithelial metaplastic 
carcinomas  
     Squamous cell carcinoma  
Adenocarcinoma with spindle cell 
metaplasia  
Adenosquamous carcinoma  
         Mucoepidermoid carcinoma  
Mixed epithelial/mesenchymal 
metaplastic carcinomas  
Lipid-rich carcinoma  
Secretory carcinoma  
Oncocytic carcinoma  
Adenoid cystic carcinoma  
Acinic cell carcinoma  
Glycogen-rich clear cell carcinoma  
 
carcinoma 
Sebaceous carcinoma  
Inflammatory carcinoma  
Lobular neoplasia 
Lobular carcinoma in situ  
Intraductal proliferative lesions 
Usual ductal hyperplasia 
Flat epithelial atypia 
Atypical ductal hyperplasia 
Ductal carcinoma in situ  
Microinvasive carcinoma 
Intraductal papillary neoplasms 
Central papilloma  
Peripheral papilloma  
Atypical papilloma 
Intraductal papillary carcinoma  
Intracystic papillary carcinoma  
Benign epithelial proliferations 
Adenosis including variants 
Sclerosing adenosis 
Myofibroblastoma  
Fibromatosis (aggressive)  
Microglandular adenosis 
Adenomyoepithelial adenosis 
Radial scar / complex sclerosing 
lesion 
Adenomas 
Tubular adenoma  
Lactating adenoma  
Apocrine adenoma  
Pleomorphic adenoma  
Ductal adenoma  
Myoepithelial lesions 
Myoepitheliosis 
Adenomyoepithelial adenosis 
Adenomyoepithelioma  
Malignant myoepithelioma  
Mesenchymal tumours 
Haemangioma  
Angiomatosis 
Haemangiopericytoma  
Pseudoangiomatous stromal 
hyperplasia 
Periductal stromal sarcoma, low 
grade 
Inflammatory myofibroblastic tumour  
Lipoma  
Angiolipoma  
Granular cell tumour  
Neurofibroma  
Schwannoma  
Angiosarcoma  
Liposarcoma  
Rhabdomyosarcoma  
Osteosarcoma  
Leiomyoma  
Leiomyosarcoma Fibroepithelial 
tumours 
Fibroadenoma  
Phyllodes tumour  
 
Mammary hamartoma 
Tumours of the nipple 
Nipple adenoma  
Syringomatous adenoma 
Pagets disease of the nipple  
Malignant lymphoma 
Diffuse large B-cell lymphoma  
Burkitt lymphoma  
Extranodal marginal-zone B-cell 
lymphoma of MALT type  
Follicular lymphoma  
Metastatic tumours 
Tumours of the male breast 
Gynaecomastia 
Carcinoma 
Invasive  
In situ 
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BIOPSY NO. AGE/SEX MENOPAUSAL STATUSSTAGE   ER-α GENOTYPEHEIGHT WEIGHT BMI
2411/08 50/F POSTMENOPAUSAL IV  Pp 161 85 32.79
2976/08 65/F POSTMENOPAUSAL III  Pp 155 53 22.06
3018/08 40/F PREMENOPAUSAL II    PP 143 70 34.23
3024/08 35/F PREMENOPAUSAL I    PP 151 78 34.21
3056/08 42/F PREMENOPAUSAL II  Pp 147 54 24.99
3174/08 56/F POSTMENOPAUSAL II  Pp 150 67 29.78
3215/08 57/F POSTMENOPAUSAL II    PP 155 65 27.06
3251/08 52/F POSTMENOPAUSAL II  Pp 154 76 32.05
4712/08 45/F PREMENOPAUSAL II    PP 163 54 20.32
5139/08 40/F PREMENOPAUSAL III    PP 139 65 33.64
5438/08 51/F POSTMENOPAUSAL II            pp 148 66 30.13
5890/08 57/F POSTMENOPAUSAL III  Pp 150 69 30.67
634/09 50/F POSTMENOPAUSAL II  Pp 155 74 30.8
1004/09 70/F POSTMENOPAUSAL I    PP 149 56 25.22
1144/09 50/F POSTMENOPAUSAL III            pp 161 50 19.29
1158/09 55/F POSTMENOPAUSAL II    PP 150 56 24.89
1918/09 40/F PREMENOPAUSAL II    PP 144 48 23.15
2041/09 46/F PREMENOPAUSAL I  Pp 144 63 30.38
2521/09 47/F POSTMENOPAUSAL III  Pp 156 60 24.65
2813/09 55/F POSTMENOPAUSAL II    PP 155 65 27.06
TABLE SHOWING GENOTYPE, MEOPAUSAL STATUS , AND BMI IN CASES
2916/09 38/F PREMENOPAUSAL II  Pp 153 55 23.5
3027/09 47/F PREMENOPAUSAL II            pp 156 76 31023
3081/09 35/F PREMENOPAUSAL II    PP 157 80 32.46
3099/09 45/F PREMENOPAUSAL III  Pp 144 48 23.15
3264/09 35/F PREMENOPAUSAL II    PP 148 66 30.13
3246/09 76/F POSTMENOPAUSAL III    PP 155 75 31.22
3345/09 45/F POSTMENOPAUSAL II  Pp 139 64 33.12
3471/09 63/F POSTMENOPAUSAL III  Pp 145 57 27.11
3518/09 40/F PREMENOPAUSAL II  Pp 153 73 1.18
3685/09 61/F POSTMENOPAUSAL IV            pp 151 78 34.21
3843/09 46/F PREMENOPAUSAL I    PP 150 56 24.89
3901/09 54/F POSTMENOPAUSAL II    PP 151 65 28.51
4087/09 36/F PREMENOPAUSAL II    PP 145 67 31.87
5521/09 65/F POSTMENOPAUSAL IV  Pp 157 78 31.64
36/10 54/F POSTMENOPAUSAL IV            pp 148 62 28.31
102/10 40/F PREMENOPAUSAL III  Pp 160 57 22.27
315/10 50/F POSTMENOPAUSAL II            pp 162 88 33.53
412/10 60/F POSTMENOPAUSAL II  Pp 151 65 28.51
515/10 40/F PREMENOPAUSAL II    PP 156 56 23.01
769/10 60/F POSTMENOPAUSAL III  Pp 143 66 32.28
989/10 52/F POSTMENOPAUSAL II  Pp 149 68 30.63
1118/10 45/F PREMENOPAUSAL III            pp 151 74 32.45
1361/10 30/F PREMENOPAUSAL IV            pp 152 71 30.73
1675/10 48/F PREMENOPAUSAL II  Pp 154 76 32.05
1832/10 61/F POSTMENOPAUSAL III  Pp 160 72 28.12
1918/10 55/F POSTMENOPAUSAL IV    PP 151 57 25
2211/10 63/F POSTMENOPAUSAL III  Pp 151 62 27.19
2410/10 54/F POSTMENOPAUSAL II  Pp 156 55 22.6
2617/10 45/F PREMENOPAUSAL III    PP 149 54 24.32
2722/10 42/F PREMENOPAUSAL III            pp 152 59 25.54
2745/10 61/F POSTMENOPAUSAL II  Pp 152 74 32.03
2829/10 60/F POSTMENOPAUSAL III            pp 144 66 31.83
2981/10 51/F POSTMENOPAUSAL II            pp 151 64 28.07
3063/103128/103 /F PREMENOPAUSAL III  Pp 164 60 22.31
3168/10 35/F PREMENOPAUSAL III            pp 156 77 31.64
3250/10 50/F POSTMENOPAUSAL III  Pp 160 56 21.87
3271/10 32/F PREMENOPAUSAL II    PP 156 83 30.8
3321/10 43/F PREMENOPAUSAL III  Pp 158 64 25.64
3418/10 63/F POSTMENOPAUSAL IV            pp 155 74 30.8
3485/10 38/F PREMENOPAUSAL II    PP 155 74 32.03
3462/10 41/F PREMENOPAUSAL I    PP 150 56 24.89
3619/10 58/F POSTMENOPAUSAL II  Pp 155 54 22.48
3742/10 35/F PREMENOPAUSAL II    PP 152 63 27.27
3810/10 39/F PREMENOPAUSAL II            pp 154 59 24.88
3864/10 44/F PREMENOPAUSAL II  Pp 161 85 32.79
3889/10 59/F POSTMENOPAUSAL III            pp 152 59 25.54
3910/10 71/F PREMENOPAUSAL III    PP 155 53 22.06
4010/10 42/F PREMENOPAUSAL III            pp 155 57 23.73
4023/10 40/F PREMENOPAUSAL II  Pp 156 74 30.41
4184/10 66/F POSTMENOPAUSAL IV    PP 156 58 23.83
4218/10 57/F POSTMENOPAUSAL II  Pp 157 60 24.34
4301/10 33/F PREMENOPAUSAL II  Pp 156 56 23.01
4330/10 70/F POSTMENOPAUSAL II    PP 154 76 32.05
4479/10 42/F PREMENOPAUSAL II  Pp 149 69 31.08
5231/10 44/F PREMENOPAUSAL IV  Pp 155 54 22.48
5536/10 68/F POSTMENOPAUSAL II    PP 157 50 20.28
108/11 64/F POSTMENOPAUSAL IV            pp 150 88 39.11
164/11 43/F PREMENOPAUSAL III            pp 146 66 30.96
512/11 40/F PREMENOPAUSAL II  Pp 145 68 32.34
741/11 37/F PREMENOPAUSAL I  Pp 156 68 27.94
841/11 72/F POSTMENOPAUSAL II    PP 151 76 33.33
1271/11 46/F POSTMENOPAUSAL III            pp 144 63 30.38
1286/11 57/F POSTMENOPAUSAL IV  Pp 164 60 22.31
1376/11 55/F PREMENOPAUSAL III    PP 152 74 32.03
1535/11 40/F PREMENOPAUSAL II    PP 153 73 31.18
1671/11 60/F POSTMENOPAUSAL III            pp 154 59 24.88
1831/11 75/F POSTMENOPAUSAL IV  Pp 157 80 32.46
1911/11 44/F PREMENOPAUSAL III    PP 155 50 20.81
1928/11 42/F PREMENOPAUSAL III  Pp 163 71 26.72
1929/11 40/F PREMENOPAUSAL II    PP 155 54 22.48
1956/11 35/F PREMENOPAUSAL II  Pp 156 60 24.65
1975/11 41/F PREMENOPAUSAL III  Pp 148 66 30.13
1989/11 65/F POSTMENOPAUSAL IV    PP 144 48 23.15
1995/11 50/F POSTMENOPAUSAL I            pp 160 57 22.27
2011/11 37/F PREMENOPAUSAL II    PP 144 48 23015
2152/11 48/F PREMENOPAUSAL II  Pp 152 74 32.03
2231/11 40/F PREMENOPAUSAL II  Pp 156 53 21.78
2511/11 62/F POSTMENOPAUSAL III  Pp 143 56 27.39
2578/11 39/F PREMENOPAUSAL II  Pp 151 78 34.21
2671/11 59/F POSTMENOPAUSAL II    PP 153 59 25.2
2781/11 37/F PREMENOPAUSAL II    PP 156 77 31.64
2890/11 42/F PREMENOPAUSAL II  Pp 155 75 31.22
3000/11 64/F POSTMENOPAUSAL III  Pp 145 57 31.87
3015/11 40/F PREMENOPAUSAL II  Pp 143 56 27.39
3781/11 67/F POSTMENOPAUSAL III    PP 149 68 30.63
3812/11 60/F POSTMENOPAUSAL IV            pp 152 56 24.24
3819/11 38/F PREMENOPAUSAL II    PP 147 54 24.99
3858/11 48/F PREMENOPAUSAL III    PP 154 73 30.78
3901/11 71/F POSTMENOPAUSAL IV  Pp 151 64 28.07
3925/11 48/F PREMENOPAUSAL III  Pp 154 59 24.88
3973/11 36/F PREMENOPAUSAL III  Pp 156 77 31.64
3981/11 65/F POSTMENOPAUSAL IV            pp 143 68 33.25
3984/11 72/F POSTMENOPAUSAL III    PP 143 56 27.39
3989/11 43/F PREMENOPAUSAL III  Pp 147 75 34.71
4012/11 38/F PREMENOPAUSAL II    PP 163 73 27.48
4128/11 42/F PREMENOPAUSAL II  Pp 168 78 27.64
4142/11 50/F POSTMENOPAUSAL II    PP 146 67 31.43
4157/11 54/F POSTMENOPAUSAL II  Pp 149 69 31.08
4210/11 36/F PREMENOPAUSAL IV            pp 157 56 22.72
4312/11 66/F POSTMENOPAUSAL III            pp 161 85 32.79
4388/11 55/F POSTMENOPAUSAL III  Pp 145 57 27.11
4433/11 35/F PREMENOPAUSAL II    PP 158 77 30.84
4459/11 68/F POSTMENOPAUSAL II            pp 156 77 31.64
4467/11 70/F POSTMENOPAUSAL III  Pp 160 78 30.47
4475/11 28/F PREMENOPAUSAL II  Pp 144 48 23.15
4496/11 37/F PREMENOPAUSAL II    PP 148 66 30.13
4510/11 65/F POSTMENOPAUSAL II    PP 155 69 28.72
4621/11 60/F POSTMENOPAUSAL II  Pp 152 56 24.24
4636/11 45/F PREMENOPAUSAL II  Pp 154 73 30.78
4645/11 50/F POSTMENOPAUSAL II            pp 148 59 26.94
4751/11 55/F POSTMENOPAUSAL II    PP 149 64 28.83
4881/11 42/F PREMENOPAUSAL III  Pp 145 57 27.11
5013/11 38/F PREMENOPAUSAL II    PP 149 64 28.83
5112/11 56/F POSTMENOPAUSAL III            pp 150 71 31.56
5132/11 40/F PREMENOPAUSAL II  Pp 157 80 32.46
5158/11 38/F PREMENOPAUSAL II            pp 163 60 22.58
5251/11 62/F POSTMENOPAUSAL III            pp 149 54 24.32
41/12 34/F PREMENOPAUSAL II  Pp 151 72 31.58
108/12 42/F PREMENOPAUSAL II    PP 152 69 29.86
325/12 39/F PREMENOPAUSAL III  Pp 159 82 32.44
421/12 54/F POSTMENOPAUSAL III            pp 159 82 32.44
471/12 72/F POSTMENOPAUSAL III    PP 145 68 32.34
527/12 40/F PREMENOPAUSAL II  Pp 158 64 25.64
721/12 44/F PREMENOPAUSAL II    PP 162 81 33.91
940/12 70/F POSTMENOPAUSAL III            pp 145 65 30.92
1015/12 65/F POSTMENOPAUSAL II    PP 145 57 27.11
1387/12 36/F PREMENOPAUSAL III            pp 147 75 34.71
1752/12 42/F PREMENOPAUSAL II    PP 161 50 19.29
1835/12 56/F POSTMENOPAUSAL II            pp 163 71 26.72
1911/12 65/F POSTMENOPAUSAL II  Pp 155 75 31.22
1987/12 40/F PREMENOPAUSAL III  Pp 160 55 21.48
2151/12 60/F POSTMENOPAUSAL III            pp 163 73 27.48
2243/12 57/F POSTMENOPAUSAL II  Pp 144 66 31.83
S.NO NAME AGE/SEX GENOTYPE RBS HEIGHT WEIGHT BMI
1 Kalavathi 32/F PP 99 166 78 28.31
2 Yuvarani 40/F Pp 129 156 72 29.59
3 Meenakshi 42/F PP 103 178 74 23.36
4 Ambujam 35/F Pp 135 150 60 26.67
5 Kanmani 46/F pp 105 153 62 26.49
6 Shanthi 38/F PP 134 178 58 18.31
7 Yasmin 45/F PP 128 164 69 25.65
8 Praveena 30/F PP 105 151 62 27.19
9 Kaviya 43/F Pp 100 160 78 30.47
10 Pushpa 52/F pp 132 148 70 31.96
11 Vijaya 40/F pp 122 156 65 26.71
12 Jayanthi 39/F PP 99 156 70 28.76
13 Nachiarammal 62/F Pp 111 170 75 25.95
14 Bhuvana 55/F Pp 124 163 68 25.59
15 Durga 43/F Pp 109 165 75 27.55
16 Chandrakal 50/F pp 100 155 55 22.89
17 Prema 34/F Pp 120 151 58 25.44
18 Rajathi 46/F PP 115 150 62 27.56
19 Archana 37/F Pp 119 153 50 21.36
20 Kannamal 65/F pp 125 163 70 26.35
21 Kanagapriya 70/F Pp 102 148 60 27.39
22 Tamilselvi 45/F PP 117 160 60 23.44
23 Aarthy 48/F Pp 107 150 62 27.56
24 Krishnaveni 56/F Pp 110 163 58 21.83
25 Swapna 40/F pp 128 158 65 26.04
26 Yalini 33/F Pp 116 156 80 32.87
27 Thahirabanu 66/F pp 106 155 62 25.81
28 Suseela 52/F Pp 130 160 85 33.2
29 Bagyam 37/F PP 122 158 62 24.84
30 Padmadevi 60/F Pp 132 152 65 28.13
31 Maheswari 55/F Pp 104 155 62 25.81
32 Aanandhi 40/F pp 109 152 56 24.24
33 Mumtaj 53/F Pp 121 161 70 27.01
34 Sulochana 50/F Pp 110 158 64 25.64
35 Selvi 32/F PP 107 150 52 23.11
36 Maharani 64/F PP 112 160 80 31025
37 Lakshmi 41/F Pp 103 156 51 20.96
38 Rekha 29/F PP 128 150 52 23.11
39 Tamilmani 28/F PP 100 161 58 22.38
40 Gayathri priya 27/F PP 97 153 50 21.36
41 Priyadharshini 26/F PP 111 158 57 22.83
42 Muralidharani 42/F Pp 129 151 66 28.95
43 Latha 34/F pp 118 162 60 22.86
44 Kohila 33/F PP 98 168 72 25.51
45 Geetharani 37/F pp 107 161 58 22.38
46 Kasthuri 35/F Pp 120 151 66 28.95
47 Vijaya lakshmi 33/F Pp 116 154 58 24.46
48 Julie 32/F Pp 119 167 68 24.38
49 Geetharani 31/F pp 106 165 65 23.88
50 Thilagavathi 55/F Pp 102 160 68 26.56
51 Parvatham 48/F Pp 117 170 60 20.76
52 Rajam 36/F pp 125 156 51 20.96
53 Rajeshwari 32/F Pp 130 157 62 25.25
54 Narayani 39/F pp 110 158 84 33.65
55 Kalimagal 47/F Pp 126 158 57 22.83
56 Hemavathy 44/F Pp 131 162 60 22.86
57 Sahiladevi 55/F Pp 113 159 70 27.69
58 Pushpavathy 62/F Pp 127 155 50 20.81
59 Devi 43/F pp 134 154 58 24.46
60 Aadhilakshmi 29/F PP 115 158 62 24.84
61 Manjula 33/F Pp 102 160 67 26.17
62 Jayalakshmi 39/F Pp 123 163 54 20.32
63 Bhargavi 56/F pp 121 160 55 21.48
64 Elizabeth 50/F Pp 107 152 55 23.81
65 Ambujalakshmi 67/F pp 125 158 92 36.85
66 Jeyashree 43/F Pp 104 155 49 20.4
67 Sharmilabanu 40/F pp 110 158 59 23.63
68 Meenakshi 65/F pp 112 150 52 23.11
69 Kanagapriya 67/F Pp 109 156 65 26.71
70 Yogalakshmi 60/F pp 127 160 65 25.39
71 Sridevi 35/F PP 122 160 75 29.3
72 Golda 42/F Pp 102 150 68 30.22
73 Sumathy 37/F pp 100 152 56 24.48
74 Hemavathy 55/F Pp 120 158 70 28.04
75 Lakshmi 63/F Pp 124 162 65 24.77
76 Neela 54/F pp 111 155 50 20.81
77 Sujatha devi 42/F Pp 100 160 48 18.75
78 Saranya 68/F pp 103 155 68 28.3
79 Devi 34/F Pp 110 155 65 27.06
80 Subbulakshmi 45/F Pp 118 159 68 26.9
81 Neelavathy 60/F PP 121 160 48 18.75
82 Swetha 42/F pp 123 160 54 21.09
83 Thangam 30/F Pp 113 158 61 24.44
84 Bagyalakshmi 44/F Pp 109 155 68 28.3
85 Kanagavalli 46/F pp 112 153 50 21.36
86 Ramani 42/F PP 118 165 60 22.04
87 Rajalakshmi 40/F Pp 110 160 54 21.09
88 Anuradha 54/F pp 107 163 58 21.83
89 Vasantha kumari 47/F Pp 117 160 58 22.66
90 Alamelu 45/F Pp 112 160 52 20.31
91 Dorathy 50/F pp 101 156 54 22.19
92 Vasuki 33/F PP 100 155 58 24.14
93 Ramadevi 42/F PP 102 164 65 24.17
94 Abidha suhara 52/F Pp 120 162 53 20.2
95 Manohari 46/F Pp 142 158 75 30.04
96 Juliet 45/F pp 137 160 54 21.09
97 Leela 34/F Pp 115 154 50 21.08
98 Lalitha 34/F Pp 140 151 56 24.56
99 Mahalakshmi 29/F pp 108 160 54 21.09
100 Devikala 35/F pp 128 154 50 21.08
101 Ambiga 46/F Pp 130 150 54 24
102 Bagyam 48/F pp 135 162 74 28.2
103 Seethalakshmi 53/F Pp 107 155 82 34.13
104 Priyadharshini 39/F Pp 99 159 65 25.71
105 Sugandhi 62/F Pp 145 163 61 22.96
106 Veeralakshmi 58/F pp 138 160 54 21.09
107 Kalpana 46/F PP 128 157 59 23.94
108 Meenakumari 38/F Pp 131 158 65 26.04
109 Subhashini 40/F Pp 123 158 62 24.84
110 Agatha 52/F pp 104 154 60 25.3
111 Shanthi 35/F PP 112 160 53 20.51
112 Vasumathi 37/F Pp 130 154 62 26.14
113 Dheepa 35/F PP 105 159 65 25.71
114 Kalaivani 44/F Pp 120 153 75 32.04
115 Geetharani 35/F pp 109 144 60 28.94
116 Gowri 45/F PP 139 170 69 23.88
117 Chitrapavai 47/F PP 128 159 66 26.11
118 Amudha 40/F pp 110 160 52 20.31
119 Dhanalakshmi 32/F Pp 126 164 50 18.59
120 Gandhimathi 35/F Pp 119 163 58 21.83
121 Mythili 48/F pp 130 155 75 31.22
122 Menaka 40/F PP 125 158 60 24.03
123 Sangeetha 45/F Pp 100 164 50 18.59
124 Pavithra 55/F Pp 103 155 75 31.22
125 Shyamiladevi 42/F Pp 107 158 54 21.63
126 Vanitha 30/F PP 99 155 60 24.97
127 Yamunadevi 62/F pp 134 151 56 24.56
128 Shiny 44/F Pp 117 158 59 23.63
129 Hemavathy 38/F Pp 123 156 55 22.6
130 Prabhavathy 45/F pp 134 157 75 30.43
131 Jothilakshmi 35/F PP 121 162 58 22.1
132 Suryalakshmi 65/F pp 103 158 72 28.84
133 Kanchan 49/F Pp 128 156 56 23.01
134 Swathi 57/F Pp 122 155 83 33.3
135 Valarmathi 46/F pp 115 166 63 22.86
136 Navamani 32/F PP 123 146 45 21.11
137 Andal 45/F Pp 113 156 68 27.94
138 Sankari 59/F pp 121 158 76 30.44
139 Sivamalar 29/F PP 111 151 51 22.37
140 Tamilselvi 41/F Pp 107 159 84 33.23
141 Umamaheshwari 40/F Pp 102 153 55 23.5
142 Kayalvizhi 35/F pp 114 155 72 32.47
143 Karpagam 38/F Pp 99 152 60 25.97
144 Manimozhi 48/F Pp 101 160 52 20.31
145 Pushpa 55/F PP 103 155 52 21.64
146 Amudha 59/F Pp 120 162 55 20.96
147 Yogeshwari 44/F pp 128 155 70 29.14
148 Komalavalli 42/F PP 104 156 53 21.78
149 Meera 40/F Pp 117 156 56 23.01
150 Padmini 45/F Pp 115 155 68 28.3
S.NO. BIOPSYNO. AGE/SEX ER STATUS   ER-α GENOTYPE
1 2411/08 50/F POSITIVE  Pp
2 2976/08 65/F POSITIVE  Pp
3 3018/08 40/F POSITIVE    PP
4 3024/08 35/F POSITIVE    PP
5 3056/08 42/F NEGATIVE  Pp
6 3174/08 56/F POSITIVE  Pp
7 3215/08 57/F NEGATIVE    PP
8 3251/08 52/F NEGATIVE  Pp
9 4712/08 45/F POSITIVE    PP
10 5438/08 51/F POSITIVE            pp
11 5890/08 57/F POSITIVE  Pp
12 634/09 50/F POSITIVE  Pp
13 1144/09 50/F NEGATIVE            pp
14 1158/09 55/F POSITIVE    PP
15 1918/09 40/F POSITIVE    PP
16 2041/09 46/F POSITIVE  Pp
17 2521/09 47/F NEGATIVE  Pp
18 2916/09 38/F POSITIVE  Pp
19 3081/09 35/F POSITIVE    PP
20 3246/09 76/F NEGATIVE    PP
21 3471/09 63/F POSITIVE  Pp
22 3518/09 40/F POSITIVE  Pp
23 3685/09 61/F NEGATIVE            pp
24 3901/09 54/F POSITIVE    PP
25 4087/09 36/F NEGATIVE    PP
26 5521/09 65/F NEGATIVE  Pp
27 515/10 40/F POSITIVE    PP
28 769/10 60/F NEGATIVE  Pp
29 989/10 52/F POSITIVE  Pp
30 1118/10 45/F NEGATIVE            pp
31 1361/10 30/F NEGATIVE            pp
32 2211/10 63/F NEGATIVE  Pp
33 2410/10 54/F POSITIVE  Pp
34 2745/10 61/F POSITIVE  Pp
35 3063/10 30/F POSITIVE  Pp
36 3168/10 35/F NEGATIVE            pp
37 3250/10 50/F NEGATIVE  Pp
38 3321/10 43/F POSITIVE  Pp
39 3864/10 44/F POSITIVE  Pp
40 3910/10 71/F POSITIVE    PP
41 4010/10 42/F NEGATIVE            pp
42 4023/10 40/F NEGATIVE  Pp
43 4184/10 66/F NEGATIVE    PP
44 4330/10 70/F POSITIVE    PP
45 4479/10 42/F NEGATIVE  Pp
TABLE SHOWING ER ALPHA GENOTYPE AND ER RECEPTOR IN CASES
46 5231/10 44/F NEGATIVE  Pp
47 4330/10 70/F POSITIVE    PP
48 4479/10 42/F NEGATIVE  Pp
49 5231/10 44/F NEGATIVE  Pp
50 512/11 40/F POSITIVE  Pp
51 741/11 37/F POSITIVE  Pp
52 1286/11 57/F NEGATIVE  Pp
53 1376/11 55/F NEGATIVE    PP
54 1831/11 75/F POSITIVE  Pp
55 1928/11 42/F NEGATIVE  Pp
56 1929/11 40/F POSITIVE    PP
57 1956/11 35/F POSITIVE  Pp
58 1975/11 41/F NEGATIVE  Pp
59 1995/11 50/F NEGATIVE            pp
60 2011/11 37/F POSITIVE    PP
61 2152/11 48/F NEGATIVE  Pp
62 2231/11 40/F POSITIVE  Pp
63 2671/11 59/F POSITIVE    PP
64 2781/11 37/F POSITIVE    PP
65 2890/11 42/F POSITIVE  Pp
66 3819/11 38/F POSITIVE    PP
67 3925/11 48/F POSITIVE  Pp
68 3973/11 36/F POSITIVE  Pp
69 4012/11 38/F POSITIVE    PP
70 4142/11 50/F POSITIVE    PP
71 4210/11 36/F NEGATIVE            pp
72 325/12 39/F NEGATIVE  Pp
73 1835/12 56/F NEGATIVE            pp
74 1987/12 40/F NEGATIVE  Pp
75 2151/12 60/F NEGATIVE            pp
